20240701-东海证券-医药生物行业周报_医保目录调整启动_精选优质个股_11页

Summary of Pharmaceutical and Biotechnology Industry Weekly Report

Market Performance

• The pharmaceutical biotechnology sector experienced significant declines, with an overall drop of 34.8% in the past week (June 24-30, 2024), outperforming only other sectors listed on Shanghai Securities classification (ranked 27 out of 31). Sub-sectors, including pharmaceutical commercial (-48.8%), medical services (-45.2%), and chemical pharmaceutical (-38.4%), saw severe losses. YTD, the sector is down 21.09%, underperforming the沪深300 index by 2.19 percentage points. Valuation indicators show the sector PE at 24.1 times, historically low, with a valuation premium of 109% relative to沪深300. Total market capitalization and trading volumes remain high, while net main force capital flow showed outflows.

Industry News

• Key updates include the National Healthcare Security Administration's release of guidelines for the 2024 medical insurance directory adjustment, extending eligibility for drug submissions and emphasizing supply chain management. Additionally, the State Drug Administration proposed revisions to expedite clinical urgent reviews of overseas marketed drugs. The National Healthcare Commission launched actions on elderly hearing health and weight management to promote public services.

Investment Suggestions

• Despite market weakness, the sector faces a supportive policy environment aimed at fostering innovation through insurance directory adjustments and negotiations. Investment recommendations include long-term positioning for high-growth areas like innovative drugs and short-term focus on fundamentally sound stocks with reasonable valuations. Suggested combinations for investment highlight include Tween Pharmaceuticals, Biodan Pharmaceutical, Fude Pharmaceutical, and others; watchlist includes Reli Pharmaceutical, Rongchang Pharmaceutical, etc. A sector outlook suggests an "overweight" rating for future 6 months, based on policy alignment.

Risk Factors

• Notable risks involve volatility from policy changes, potential underperformance of companies due to financial or operational issues, and safety incidents with pharmaceutical and medical products, which could negatively impact the overall market.